The prognostic value of sulphomucin positive intestinal metaplasia in the development of gastric cancer.
Gastric biopsy specimens from 230 patients with chronic atrophic gastritis were investigated with the use of mucin stains for the presence and type of intestinal metaplasia. Metaplasia was not shown in 59 cases; 92 of the 171 cases with metaplasia were sulphomucin positive and 79 were negative. The patients were followed-up from 1976 to 1985. Eight patients were registered as having gastric cancer over this period. However, five of them had to be eliminated from the study because on careful review of all the clinical data it was clear that they had gastric cancer at the time of the biopsy. Two of the three remaining patients had sulphomucin negative biopsies. Thus, only one patient out of 90 with chronic atrophic gastritis and sulphomucin positive intestinal metaplasia developed gastric cancer when followed-up for 8-9 years. None of the patients with unequivocal type IIb metaplasia developed gastric cancer. We conclude that sulphomucin positive intestinal metaplasia does not identify a high risk group and its recognition is thus of no value in surveillance for gastric cancer.
D000328:Adult; D000368:Aged; D005260:Female; D005757:Gastritis, Atrophic / Q000150:complications / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D007422:Intestines / Q000473:pathology; D008297:Male; D008679:Metaplasia / Q000378:metabolism; D008875:Middle Aged; D009077:Mucins / Q000378:metabolism*; D011379:Prognosis; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000209:etiology* / Q000517:prevention & control
D009077:Mucins; C012564:sulfomucin